share_log

PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate

Benzinga ·  Apr 25 16:39

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.29) by 6.98 percent. The company reported quarterly sales of $210.118 million which beat the analyst consensus estimate of $169.703 million by 23.82 percent. This is a 4.66 percent decrease over sales of $220.382 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment